NR1H4 and metabolic dysfunction-associated steatohepatitis: FXR activation is currently evaluated as therapeutic concept for the treatment of severe liver disorders such as non-alcoholic steatohepatitis (NASH) and primary biliary cirrhosis (PBC) with obeticholic acid (OCA) as experimental FXR agonist in advanced clinical development9, 10, 11.